Reverse Payment Settlements in Biologics: A Comparative Competition Law Analysis

Posted On - 17 April, 2026 • By - Aniket Ghosh

Introduction

Biologics are medicinal products derived from living cells that have transformed the treatment of chronic and life-threatening diseases, including cancer, diabetes, and autoimmune disorders. Unlike small-molecule drugs, biologics are structurally complex and require sophisticated manufacturing processes, extensive clinical evaluation, and stringent regulatory approval pathways. These features significantly increase development costs, often limiting accessibility. 

Biosimilars provide a cost-effective alternative to reference biologics. While not identical, they demonstrate a high degree of similarity in safety, efficacy, and quality, thereby expanding access to critical therapies particularly in price-sensitive markets. 

India has emerged as a significant player in the global biosimilars market, with manufacturers such as Biocon, Dr. Reddy’s Laboratories, and Intas Pharmaceuticals. The regulatory framework, governed jointly by the Department of Biotechnology (DBT) and the Central Drugs Standard Control Organisation (CDSCO), has evolved considerably. Under the Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorisation in India (2022), biosimilars must undergo extensive comparative analytical and clinical studies, with conditional waivers for confirmatory Phase III trials where robust pharmacokinetic (PK) and pharmacodynamic (PD) data are available.1 

India’s competitive advantage lies in its combination of scientific capability and cost-efficient manufacturing, enabling broader global access to biologic therapies. 

The Concept of Pay-for-Delay

Reverse payment settlements commonly termed “pay-for-delay” agreements, arise when a patent-holding originator compensates a generic or biosimilar entrant to delay market entry. These arrangements typically emerge in the context of patent litigation settlements, allowing parties to avoid prolonged legal disputes. 

Such agreements have attracted intense antitrust scrutiny globally. In FTC v. Actavis, Inc., 570 U.S. 136 (2013)2, the U.S. Supreme Court held that reverse payment settlements are not immune from antitrust review merely because they fall within the “scope of the patent.” Instead, they must be assessed under the rule of reason, with large and unexplained payments serving as potential indicators of anti-competitive intent. 

Similarly, the European Commission, following its Pharmaceutical Sector Inquiry (2009)3, has actively pursued enforcement against agreements delaying generic entry, treating such arrangements as restrictions of competition by object or effect under EU competition law. 

Although historically associated with small-molecule drugs, analogous strategies are increasingly visible in the biologics sector. These include patent thickets, restrictive licensing practices, and exclusive supply arrangements, all of which may collectively delay biosimilar entry. Given the complexity and cost of biosimilar development, the sector is particularly susceptible to such conduct. 

In India, potential pay-for-delay concerns fall at the intersection of the Patents Act, 1970 and the Competition Act, 2002. 

The Patents Act incorporates safeguards against abuse of patent rights. Section 3(d) restricts patentability of new forms of known substances absent enhanced therapeutic efficacy, thereby curbing “evergreening.” Section 844 provides for compulsory licensing where reasonable public requirements are unmet, prices are unaffordable, or the invention is not worked in India. 

The Competition Act, 2002, addresses anti-competitive agreements and abuse of dominance. Section 3 prohibits agreements that cause or are likely to cause an appreciable adverse effect on competition (AAEC), while Section 4 prohibits abuse of a dominant position, including exclusionary conduct and denial of market access. Importantly, Section 3(5) provides a limited exemption for reasonable conditions necessary to protect intellectual property rights, but does not grant blanket immunity from competition scrutiny. 

While Indian jurisprudence has not yet directly addressed pay-for-delay settlements in the biosimilars context, the Competition Commission of India (CCI) has signalled caution toward agreements that may extend exclusivity beyond legitimate patent rights. Regulatory concern is particularly evident in relation to restrictive licensing and enforcement strategies that may hinder market entry. 

Scientific and Commercial Dynamics of Biosimilars 

Unlike generic drugs, biosimilars cannot be exact replicas due to the inherent variability of biological systems. Consequently, regulatory approval is based on a comparative assessment framework, rather than mere chemical identity, as emphasised by the World Health Organization.5 

Price reductions from biosimilars are typically more modest than those from generics (approximately 15–30%, compared to 20–80%). However, given the high baseline cost of biologics, even these reductions generate substantial economic benefits. 

Globally, regulatory milestones have shaped biosimilar competition. The European Medicines Agency (EMA) pioneered biosimilar approvals in 2006. In the United States, the Biologics Price Competition and Innovation Act (BPCIA), 2009, established an abbreviated approval pathway and introduced the “patent dance” framework for resolving patent disputes. 

India, notably, approved early biosimilars prior to formal guidelines and has since aligned its regulatory framework with global standards while maintaining a public health-oriented approach. 

Competing Perspectives on Pay-for-Delay 

Arguments in Favour: 

  • Litigation Efficiency: Settlements reduce costly and uncertain patent litigation.  
  • Exercise of Patent Rights: Patent holders are entitled to exclude competitors within the patent term.  
  • Commercial Certainty: Settlements may ensure predictable supply chains and market planning.  
  • R&D Incentives: Revenue protection is critical to sustaining innovation, particularly in high-cost biologics.  

Arguments Against: 

  • Delayed Access: Such agreements postpone the availability of affordable alternatives.  
  • Market Distortion: Payments to delay entry undermine competitive market structures.  
  • Regulatory Circumvention: They may effectively extend exclusivity beyond statutory limits.  
  • Chilling Effect: Potential entrants may be discouraged from challenging weak patents.  

Empirical studies in the United States have estimated substantial consumer welfare losses arising from delayed generic entry. In biologics, these concerns are amplified due to higher price points and limited competition. 

Comparative Jurisprudence 

United States 

Following Actavis, reverse payment settlements are analysed under antitrust principles, with emphasis on the size and justification of payments. In Amgen Inc. v. Sandoz Inc., 582 U.S. 121 (20176), the Supreme Court clarified that participation in the BPCIA’s “patent dance” is optional, thereby limiting procedural tools that could delay biosimilar entry. 

European Union 

Under Articles 101 and 102 of the Treaty on the Functioning of the European Union (TFEU), anti-competitive agreements and abuse of dominance are prohibited. In Lundbeck, the European Commission imposed significant fines on the originator for agreements delaying generic entry, signalling a strict enforcement stance. 

India 

Indian enforcement remains cautious and effects-based. In Biocon Ltd. v. F. Hoffmann-La Roche AG (CCI, 2017)7, the CCI held that the exercise of patent rights does not constitute abuse absent demonstrable anti-competitive effects. Subsequent cases have reiterated that settlements must not exceed the legitimate scope of patent protection or create unjustified barriers to entry. 

Additionally, the Supreme Court’s decision in Novartis AG v. Union of India (2013) reinforces India’s strict patentability standards, limiting strategies aimed at prolonging exclusivity. 

Conclusion 

India’s biosimilars sector is rapidly expanding, but the legal framework addressing reverse payment settlements remains underdeveloped. A calibrated approach is necessary to balance innovation incentives with competition and public health objectives. 

Policy priorities should include: 

  • Clearer enforcement standards under Sections 3 and 4 of the Competition Act;  
  • Greater transparency in patent settlement agreements;  
  • Enhanced institutional coordination between the CCI, the Patent Office, and CDSCO.  

Comparative experience from the United States and European Union demonstrates that patent settlements cannot evade competition scrutiny merely by invoking intellectual property rights. As biologics assume greater importance in global healthcare, India must ensure that patent protections do not evolve into mechanisms for undue market foreclosure.